<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03560570</url>
  </required_header>
  <id_info>
    <org_study_id>CNIL2126725</org_study_id>
    <nct_id>NCT03560570</nct_id>
  </id_info>
  <brief_title>Study of Hemostasis in Patients With Congenital Disorder of Glycosylation</brief_title>
  <acronym>CDG-Coag</acronym>
  <official_title>Evaluation of Global Coagulation Balance of 57 Patients With Congenital Disorder of Glycosylation Using the Thrombin Generation Assay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - H么pitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - H么pitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the coagulation balance in a cohort of congenital
      disorder of glycosylation (CDG) patients using conventional tests combined with an integrated
      approach of their coagulation disorders in using TGA in the absence or presence of sTM. Thus,
      investigators aimed to define if the hemostatic balance in CDG patients, is preserved despite
      of combined deficiencies in both procoagulant and anticoagulant factors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In CDG, coagulation abnormalities, affecting both pro and anticoagulant factors, could
      account for onset of acute microvascular events in these patients. In line with this
      hypothesis, a previous study reported a correlation between low activity of anticoagulant
      factors and thrombosis, although stroke-like episodes, the most frequent event, were not
      analyzed in this study. Moreover, the hemostatic balance is usually investigated by global
      coagulation tests such as the prothrombin time (PT) and the activated partial thromboplastin
      (aPTT). However, these tests have serious limitations. First, they explore only 5 % of the
      whole generated thrombin, enough to clot the plasma. In addition, global tests are
      insensitive to the coagulation inhibitors, especially the PC system which cannot be mobilized
      in the absence of thrombomodulin (TM). The thrombin generation assay (TGA), is also a global
      coagulation assay, but it allows exploration of the whole thrombin formation process from its
      generation to its inhibition. Moreover, combining different analytical conditions, all the
      anticoagulant systems could be investigated, including antithrombin in basal conditions and
      the PC system in the presence of soluble TM (sTM)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2014</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">January 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of haemostatic balance using thrombin generation assay</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The assessment of thrombin generation in presence or not of soluble thrombomodulin allows to determine a ratio &quot;R&quot; (without units) calculated as follow : ETP (endogenous thrombin potential) with soluble thrombomodulin (nM/min)/basal ETP (nM/min). This ratio reflects the hypocoagulant or hypercoagulant profile.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">57</enrollment>
  <condition>Congenital Disorders of Glycosylation</condition>
  <arm_group>
    <arm_group_label>Event group</arm_group_label>
    <description>CDG with antecedent of stroke-like, thrombosis or haemorrhages</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non event group</arm_group_label>
    <description>CDG without antecedent of stroke-like, thrombosis or haemorrhages</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Healthy subject</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Coagulation assay</intervention_name>
    <description>Conventional coagulation assays: prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen, factor II, FV, FVII, FX, FVIII, FIX, FXI, FXII, d-dimers, antithrombin, protein C, protein S Thrombin generation assay: in presence or not of soluble thrombomodulin</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Event group</arm_group_label>
    <arm_group_label>Non event group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical data collection</intervention_name>
    <description>At inclusion, we recorded clinical data about the disease (type and form of congenital disorder of glycosylation, and antecedent of microvascular event: thrombosis, stroke-like or hemorrhages)</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Event group</arm_group_label>
    <arm_group_label>Non event group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        CDG cohort comes from reference center of rares metabolic diseases of Necker-Enfants
        malades hospital in Paris
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -Clinical diagnosis of Congenital Disorder of Glycosylation (CDG)

        Exclusion Criteria:

        - no exclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Delphine Borgel, PharmaD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - H么pitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H么pital Necker Enfants malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>April 6, 2018</study_first_submitted>
  <study_first_submitted_qc>June 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>August 30, 2018</last_update_submitted>
  <last_update_submitted_qc>August 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stroke-like</keyword>
  <keyword>thrombosis</keyword>
  <keyword>haemorrhages</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Disorders of Glycosylation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

